The Peptide Rush Has Begun

The U.S. Department of Health and Human Services (HHS) has announced that it will not enforce penalties on licensed pharmacists who provide certain unapproved peptides to consumers, according to a new policy published on October 28 in the Federal Register. Peptides are short chains of amino acids that people inject into their bodies, and HHS Secretary Robert F. Kennedy Jr. has expressed enthusiasm for these unapproved drugs, despite their largely unproven benefits.

The U.S. Food and Drug Administration (FDA) banned peptides in 2023 due to safety concerns. However, an FDA committee held a meeting in July to review the evidence on peptides and decide whether to allow pharmacies to dispense them without scientific review. The committee, composed of new appointees affiliated with companies interested in promoting peptides, recommended allowing six peptides to be dispensed by specialty pharmacies.

Despite FDA staff advising against this move, HHS Secretary Kennedy signed the new policy, stating that "significant interest" in obtaining these peptides from compounding pharmacies exists. The policy aims to expand and improve patient access to these peptides, which include BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. The decision has been welcomed by companies like Hims & Hers, which had planned to introduce peptides in 2026, and could potentially generate a market worth $3.3 billion.

Public-health professionals, however, have expressed concerns about the lack of scientific evidence supporting the use of peptides and fear that patients may be treated as "guinea pigs." Critics argue that allowing peptides to bypass a rigorous FDA approval process is unprecedented and potentially dangerous to consumers. Compounding pharmacies, which specialize in producing customized medications, are under scrutiny for their role in dispensing these untested drugs.